Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection.
BACKGROUND
A study was designed to estimate relative analytic sensitivity and window-period (WP) closure and to project incremental yield of newer HBsAg tests, pooled-sample NAT, and single-sample NAT, compared to currently licensed HBsAg tests.


METHODS
HBV DNA and HBsAg test results for 23 HBV seroconversion (SC) panels were first analyzed to construct a model of primary HBV viremia. One-hundred representative samples were then selected from 10 panels and coded with 28 analytical controls. All 128 samples were tested by seven HBsAg tests and by four pooled-sample and three single-sample NAT assay formats. Results were analyzed to obtain differential times to HBV detection and combined with HBV incidence rates to project comparative yields.


RESULTS
HBV doubling time during the ramp-up phase was estimated at 2.56 days. HBsAg concentrations at cutoff for new tests ranged from 0.07 to 0.12 ng per mL, compared with 0.13 to 0.62 ng per mL for licensed tests. Estimated viral load at cutoff ranged from 102 to 267 IU per mL for new tests and from 363 to 1069 IU per mL for licensed tests. HBsAg tests detected 31 to 63 percent of early ramp-up phase samples in the 100-member seroconversion panel study, while pooled-sample NAT detected 55 to 71 percent and single-sample NAT, 82 to 99 percent. Compared with currently licensed HBsAg assays, newer HBsAg assays would reduce the WP by 2 to 9 days; pooled-sample NAT would reduce the WP by 9 to 11 days; and single-sample NAT would reduce the WP by 25 to 36 days.


CONCLUSIONS
Newer HBsAg tests would be expected to detect an additional 15 to 21 infected units per 107 donations, compared to licensed HBsAg tests. Sensitivity, WP closure, and yield projections for newer HBsAg assays and pooled-sample NAT are comparable. Single-sample NAT would increase yield by 13 to 15 units per 107 donations over pooled-sample NAT and newer HBsAg assays and by 35 to 50 units per 107 donations over currently licensed HBsAg assays.
Biswas
Robin
R
Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, Maryland, USA.
Tabor
Edward
E
Hsia
Chu Chieh
CC
Wright
David J
DJ
Laycock
Megan E
ME
Fiebig
Eberhard W
EW
Peddada
Lorraine
L
Smith
Richard
R
Schreiber
George B
GB
Epstein
Jay S
JS
Nemo
George J
GJ
Busch
Michael P
MP
D000208:Acute Disease; D004279:DNA, Viral / Q000097:blood*; D006509:Hepatitis B / Q000175:diagnosis* / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006801:Humans; D016133:Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D019562:Viral Load
D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens